Valeo Health Secures $12 Million in Series B Funding, Raising Total Investment to $20 Million 

Valeo Health, a UAE-based healthtech innovator, has successfully raised $12 million in its Series B funding round, bringing its total investment to $20 million. The round was led by Flintera, with participation from existing investors Nuwa Capital, FJ Labs, Oryx, and Mindshift Capital, alongside new investors Oraseya and Eirad. This funding underscores the increasing confidence in Valeo Health’s AI-driven, personalised healthcare solutions.

Founded in 2021 by Sundeep Sahni, Nadine Karadag, and Ankur Majumder, Valeo Health is revolutionizing healthcare by providing personalised, science-backed solutions tailored to individual needs. The company’s proprietary Longevity technology enables at-home healthcare services, proactive treatment plans, and real-time health monitoring, setting a new standard for digital health solutions across the GCC.

The fresh capital will be used to scale Valeo Health’s AI technology, enhance product offerings, and expand its reach in key markets, including Saudi Arabia, the UAE, and the broader GCC region. The company’s mission is to make personalised healthcare more accessible, empowering individuals with data-driven insights to proactively manage their well-being.

CEO and Co-founder Sundeep Sahni expressed enthusiasm for the investment, stating, “We are thrilled by the strong support from our investors as we continue to redefine how people engage with their health. This funding allows us to scale our technology, refine our offerings, and ensure more individuals benefit from proactive healthcare solutions.” Co-founder Nadine Karadag added, “This investment validates our team’s hard work and strengthens our ability to deliver personalised healthcare on a larger scale.”

Flintera, the lead investor, emphasized the significance of this investment, with a spokesperson stating, “Valeo is shaping the future of preventive healthcare in the region. At Flintera, we support founders who merge advanced technology with a scalable vision. HealthTech is a priority sector for us, and we are excited to back a company that aligns with our investment philosophy.”

Nuwa Capital, an early backer of Valeo Health, also reaffirmed its commitment, with Partner Nitin Reen commenting, “Since our initial investment in 2021, we’ve seen the Valeo team execute with precision and deliver impressive year-over-year growth. This round enables them to deepen their customer-centric approach and provide even greater value to their users.”

As a trusted name in the GCC’s healthtech space, Valeo Health is committed to transforming the future of healthcare through personalised, AI-powered solutions. With this latest investment, the company is well-positioned to expand regionally and continue driving innovation in the digital health sector.